[Influence of chronic pain in osteoarthritis on the risk of cardiovascular diseases and modern methods of drug prevention]. / Vliyanie khronicheskoi boli pri osteoartrite na risk razvitiya serdechno-sosudistykh zabolevanii i sovremennye sposoby ikh lekarstvennoi profilaktiki.

The purpose of the review of scientific medical literature was to evaluate the data of the epidemiology of osteoarthritis (OA) and cardiovascular diseases (CVD) with the analysis of risk factors, pathophysiological and pathobiochemical mechanisms of the relationship between OA and the risk of developing CVD in the presence of chronic pain, modern strategies for screening and management of this cohort of patients, the mechanism of action and pharmacological effects of chondroitin sulfate (CS). Conclusions were drawn about the need for additional clinical and observational studies of the efficacy and safety of the parenteral form of CS (Chondroguard) in patients with chronic pain in OA and CVD, improvement of clinical recommendations for the treatment of chronic pain in patients with OA and cardiovascular risk, with special attention to interventions that eliminate mobility restrictions in patients and the inclusion of basic and adjuvant therapy with DMOADs to achieve the goals of multipurpose monotherapy in patients with contraindications to standard therapy drugs.

[Imaging of brain activity using fMRI in a patient with subjective cognitive decline]. / Vizualizatsiya mozgovoi aktivnosti s pomoshch'yu fMRT u patsientki s sub"ektivnym kognitivnym snizheniem.

In clinical practice, subjective cognitive decline (SCD) is often difficult to diagnose because it is not detected by standard neuropsychological and cognitive tests.The described clinical case is presented to demonstrate the difficulties of diagnosis and treatment choice in a patient with SCD. fMRI might be considered as an instrumental method to analyze the functional relationship between the activity of brain structures and cerebral circulation in patients with SCD. Patient clinical and neuropsychological data with a detailed description of fMRI with a cognitive paradigm are presented. The article is focused on the early diagnosis of SCD and the prognostic assessment of the transition of SCD to dementia.

[Treatment of diseases with consequences of traumatic brain injury]. / Lechenie bol'nykh s posledstviyami cherepno-mozgovoi travmy.

Traumatic brain injury (TBI) is one of the leading causes of neurological morbidity, disability and mortality in all age groups of the population. As a result of the general increase in the number of cases of brain injuries, there is a significant increase in the consequences of TBI, the dominant part of which is asthenic, vegetative, cognitive, emotional and liquorodynamic disorders. Therapeutic measures in the long-term period of TBI should be carried out intensively as in the first 12 months. after TBI, and in the future, considering the ongoing processes of morphofunctional maturation of the CNS and high brain plasticity, especially in childhood. Syndromic treatment should be differentiated and pathogenetically substantiated. The article covers in detail the modern methods of drug therapy in patients with remote residual effects of brain injury. The high efficiency of the use of the neuroprotective drug Cortexin in the correction of the consequences of TBI was shown.

[Results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology]. / Itogi kruglogo stola: sovremennye podkhody k medikamentoznoi terapii kognitivnykh narushenii pri tserebrovaskulyarnoi patologii.

On June 25-26, 2021, a round table was held in Kazan with the participation of leading neurologists of Russia, where the issues of treatment of patients with cognitive impairment due to cerebrovascular diseases were discussed. Cognitive disorders of vascular genesis (VCD) are widespread in the population, are a common cause of a decrease in the quality of life and restriction of daily activity. The cause of VCD is both acute and chronic cerebrovascular diseases. An effective way to prevent VCD is to control cardiovascular risk factors, ensure a sufficient level of cognitive and physical activity throughout life. The role of drug therapy, aimed, among other things, at normalizing metabolic processes in the brain, is extremely important. The data on the mechanisms of action of the new domestic drug prospecta, the results of its clinical trials in patients with VCD are presented.

[Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke]. / Farmakoékonomicheskii analiz neiroprotektorov, primeniaemykh v terapii ishemicheskogo insul'ta.

AIM: To perform a pharmacoeconomic analysis of the most frequently prescribed neuroprotective medicines for treating patients with mild ischemic stroke in the acute and early rehabilitation periods in the Russian Federation. MATERIAL AND METHODS: Three medical technologies were compared: ethylmethylhydroxypyridine succinate (mexidol), inosine + nicotinamide + riboflavin + succinic acid (cytoflavin) and a deproteinized hemoderivate of the blood of calves (actovegin). Cost minimization analysis, budget impact analysis and sensitivity analysis were performed based on the indirect comparison results. RESULTS: Efficacy analysis shows that mentioned above medicines have the same efficacy: mean difference mexidol is 0,2 (CI min 0,25; max 0,65), cytoflavin - 0,61 (CI min 0,23; max 0,99), actovegin 0,2 (CI min 0,18; max 0,22). The cost minimization analysis for the Russian Federation shows that mexidol therapy is associated with the lowest costs, while savings are observed both in the evaluation of total costs and separate components: intravenous ampoules and tablet forms. The savings in comparison with cytoflavin and actovegin are 231 RUB and 12,872 RUB, respectively. These savings will be enough to treat five patients with ischemic stroke (IS) with mexidol. Moreover, oral mexidol therapy is cheaper than the same dosage forms of cytoflavin and actovegin by 481 RUB and 3,164 RUB, respectively. This is an advantage for the treatment of population at the outpatient stage. Budget impact analysis has shown that the budget for the medicines for treating IS at the current distribution between treatment regimens, is estimated at 1.99 BN RUB. The increase in the proportion of patients receiving mexidol by 10% reduces total costs to 1.75 BN RUB, which is 240 M RUB less than current costs. With these savings 85 thousand patients with IS could be treated. The sensitivity analysis reveals that the result of the cost minimization analysis and the budget impact analysis remain stable when both the amount of the population and the cost of 1 mg of mexidol vary from -10% to + 10%. CONCLUSIONS: Mexidol has the same efficacy as alternatives. However mexidol is superior to cytoflavin and actovegin in terms of cost minimization analysis. The savings from one course of alternatives will cover costs of treatment of five patients with IS using mexidol. The increase in the proportion of patients receiving mexidol is associated with savings, which allows us to consider mexidol therapy of mild IS as budget-saving in the Russian Federation.

[Oxidative stress and inflammation as links in a chain in patients with chronic cerebrovascular diseases]. / Okislitel'nyi stress i vospalenie kak zven'ia odnoi tsepi u bol'nykh s khronicheskimi tserebrovaskuliarnymi zabolevaniiami.

Cerebrovascular diseases (CVD) are the main cause of death and permanent disability. The urgency of the problem of chronic CVD is associated with an increase of the absolute number of elderly and senile age in the population, a trend towards slowly increasing, sluggish pathological processes. It is obvious that any somatic disease in such patients is comorbid to cerebrovascular diseases that suggests a unified mechanism of the pathogenesis for both the main and concomitant diseases. The article notes that microangiopathy is the most common cause of CVD. The main etiopathogenetic factor affecting cerebral vessels of small caliber is endothelial dysfunction, systemic inflammation and oxidative stress. Understanding the molecular components that underlie functional abnormalities and damage of small blood vessels gives the key to the modern strategies in therapy, forming the foundation for an adequate pathogenetically justified therapy. This impact should be gradual, complex and aimed at correcting pathochemical disorders in general and neurotransmitter imbalance in particular. The drug dipyridamole, which has pleiotropic effects, can be considered as one of the pathogenetically justified means in complex drug therapy in patients with CVD.

[Phospholipids metabolism disorders in acute stroke].

The disturbances of cerebral circulation results in the violation of phospholipid metabolism. Activation of lipid peroxidation and protein kinase C and release of intracellular calcium leads to disruption of the homeostasis of phosphatidylcholine. The use of cytidine-5-diphosphocholine, which is used as an intermediate compound in the biosynthesis of phospholipids of the cell membrane, helps to stabilize cell membranes, and reduce the formation of free radicals.

[From the conception of «oxidizing stress¼ to the conception of «cell signaling modulation¼].

We discuss the current conception of "oxidizing stress" which covers a wide group of various interrelated phenomena including higher production of reactive oxygen species (ROS) and oxidative damage of cellular molecular components. Currently the term of oxidizing stress is used for the description of pro-oxidant and antioxidant imbalance, with the prevalence of the former, that results in the damage of biological molecules and cellular structures. However ROS do not play a single role in oxidative metabolism. There are also active nitrogen forms, reactive forms of carbon, chlorine and sulphur. These highly reactive molecules are involved in many reactions and play a great role in the regulation of different metabolic processes in the body. These reactions underlie such pathological processes as heart ischemia, atherosclerosis, cerebral ischemia and different types of inflammation. An effect of highly reactive molecules on the destruction of biologically important molecular in different stressful conditions is determined by the reactions they are involved in. But the balance of oxidizers and antioxidants should not be considered as a unified system because main cellular redox systems are not in the redox equilibrium. In this view, a search for an optimal oxidizer that impacts on the modulation of cellular signal pathways related with ROS development is the most effective way in the development of antioxidant therapy.